Last reviewed · How we verify
Placebo (20% Intralipid)
Placebo (20% Intralipid) is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 3 development.
Placebo (20% Intralipid) does not have an active pharmacological effect; it serves as a control in clinical trials.
At a glance
| Generic name | Placebo (20% Intralipid) |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Intralipid is a fat emulsion used as a vehicle for parenteral nutrition. In clinical trials, it can serve as a placebo to control for the physical effects of receiving an intravenous solution.
Approved indications
Common side effects
- Injection site reaction
Key clinical trials
- Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PHASE2)
- A-TANGO Phase 2 Study (PHASE2)
- Reversing Glucose and Lipid-mediated Vascular Dysfunction (EARLY_PHASE1)
- South African Male User Research on Acceptability of Implants and Injections (NA)
- Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism (PHASE1, PHASE2)
- Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle (NA)
- The Cardioprotective Effect of Intralipid in Decreasing the Ischemic Insults During Off-pump Coronary Artery Revascularization (PHASE4)
- Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (20% Intralipid) CI brief — competitive landscape report
- Placebo (20% Intralipid) updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI